Complete Cytoreduction Followed by IP and Systemic Chemotherapies for Gastric Cancer With Peritoneal Carcinomatosis

Background: Approximately 15% of gastric adenocarcinoma patients presents with peritoneal carcinomatosis (PC) at the first encounter and is regarded as an unresectable and end-stage disease. The recommended treatment with palliative chemotherapy alone yields a poor clinical efficacy. Emerging evidences suggest the survival benefits of complete cytoreductive surgery (CRS) combined with normothermic intraperitoneal chemotherapy (N-IPEC) for gastric adenocarcinoma with limited PC. Objective: To evaluate the 6-month disease control rate (DCR) of complete CRS combined with N-IPEC and systemic chem

Trial Details

NCT ID
NCT04547725
Phase
NA
Sponsor
National Taiwan University Hospital
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • CRS followed by IP and systemic chemotherapies
Locations (sample)
  • Taipei, Taiwan|25.05306,121.52639

Key Eligibility Criteria

  • Age 20 to 75 years old.
  • Blood tests:
  • White blood cells \> 4,000/mm3, neutrophils \> 1,500/mm3, platelets \> 100,000/mm3.
  • Serum creatinine \< 1.5 mg/dl or creatinine clearance \> 60 ml/min.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →